IP Library Granted Patent US 9,562,072
Granted Patent B2
US 9,562,072 · App. 14/364,466 · Granted Feb 7, 2017

Compositions and methods for regulating glucose metabolism

Inventor: Katerina Akassoglou (San Francisco, CA)
Assignee: The J. David Gladstone Institutes
C07K7/08A61K38/10A61K38/46C07K14/7151C12Q1/54C12Y306/05002G01N33/60G01N33/66G01N2500/00G01N2800/042
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,562,072
App. No.
14/364,466
Granted
Feb 7, 2017
Kind
B2
Abstract

The present disclosure provides compositions for regulating glucose metabolism. The compositions provide for reduced levels of p75 NTR and/or reduced binding of p75 NTR to a GTPase such as Rab31 or Rab5. The compositions are useful in methods of regulating glucose metabolism, which methods are also provided.

Claims (58)

1. A method of reducing blood glucose levels and/or insulin resistance in an individual, the method comprising administering to the individual an effective amount of an agent that inhibits binding between the intracellular domain of the p75 neurotrophin receptor (p75 NTR ) and an intracellular GTPase selected from Rab31 and Rab5, wherein the agent is a peptide comprising an amino acid sequence selected from:

a)

LLASWATQDSATLDA;

(SEQ ID NO: 1)

b)

X 1 LASWATQDSATLDA;

(SEQ ID NO: 2)

c)

LX 1 ASWATQDSATLDA;

(SEQ ID NO: 3)

d)

LLX 1 SWATQDSATLDA;

(SEQ ID NO: 4)

e)

LLAX 1 WATQDSATLDA;

(SEQ ID NO: 5)

f)

LLASX 1 ATQDSATLDA;

(SEQ ID NO: 6)

g)

LLASWX 1 TQDSATLDA;

(SEQ ID NO: 7)

h)

LLASWAX 1 QDSATLDA;

(SEQ ID NO: 8)

i)

LLASWATX 1 DSATLDA;

(SEQ ID NO: 9)

j)

LLASWATQX 1 SATLDA;

(SEQ ID NO: 10)

k)

LLASWATQDX 1 ATLDA;

(SEQ ID NO: 11)

l)

LLASWATQDSX 1 TLDA;

(SEQ ID NO: 12)

m)

LLASWATQDSAX 1 LDA;

(SEQ ID NO: 13)

n)

LLASWATQDSATX 1 DA;

(SEQ ID NO: 14)

o)

LLASWATQDSATLX 1 A;

(SEQ ID NO: 15)

and

p)

LLASWATQDSATLDX 1 ,

(SEQ ID NO: 16)

where X 1 is any amino acid.

2. The method of claim 1 , wherein the peptide comprises at least one non-coded amino acid.

3. The method of claim 1 , wherein the peptide comprises at least one D-amino acid.

4. The method of claim 1 , wherein the peptide comprises a non-peptide isosteric linkage.

5. The method of claim 1 , wherein the peptide has a length of from 15 amino acids to about 50 amino acids.

6. The method of claim 1 , wherein the peptide is cyclized.

7. The method of claim 1 , wherein the peptide comprises a protein transduction domain (PTD).

8. The method of claim 1 , wherein the agent is a peptide comprising the amino acid sequence LLASWATQDSATLDA (SEQ ID NO:1).

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 29, 2015
From: J. DAVID GLADSTONE INSTITUTES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 036222/0859 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2014
From: AKASSOGLOU, KATERINA
To: THE J. DAVID GLADSTONE INSTITUTES
Reel/Frame 033212/0547 →
Continuity (2)
Provisional Application 61580523 · Dec 27, 2011
Related Publication 20140315799A1 · Oct 23, 2014